FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2605847125> ?p ?o ?g. }

• W2605847125 endingPage "242" @default.
• W2605847125 startingPage "235" @default.
• W2605847125 abstract "Background: Gemcitabine (2′,2′-difluoro-2′-deoxycytidine) is a nucleoside analog used as a single agent and in combination regimens for the treatment of a variety of solid tumors. Several studies have shown a relationship between gemcitabine peak plasma concentration (C max ) and hematological toxicity. An immunoassay for gemcitabine in plasma was developed and validated to facilitate therapeutic drug monitoring (TDM) by providing an economical, robust method for automated chemistry analyzers. Methods: A monoclonal antibody was coated on nanoparticles to develop a homogenous agglutination inhibition assay. To prevent ex vivo degradation of gemcitabine in blood, tetrahydrouridine was used as a sample stabilizer. Validation was conducted for precision, recovery, cross-reactivity, and linearity on a Beckman Coulter AU480. Verification was performed on an AU5800 in a hospital laboratory. A method comparison was performed with (LC-MS/MS) liquid chromatography tandem mass spectrometry using clinical samples. Selectivity was demonstrated by testing cross-reactivity of the major metabolite, 2′,2′-difluorodeoxyuridine. Results: Coefficients of variation for repeatability and within-laboratory precision were <8%. The deviation between measured and assigned values was <3%. Linear range was from 0.40 to 33.02 μ/mL (1.5–125.5 μM). Correlation with validated LC-MS/MS methods was R 2 = 0.977. The assay was specific for gemcitabine: there was no cross-reactivity to 2′,2′-difluorodeoxyuridine, chemotherapeutics, concomitant, or common medications tested. Tetrahydrouridine was packaged in single-use syringes. Gemcitabine stability in whole blood was extended to 8 hours (at room temperature) and in plasma to 8 days (2–8°C). Conclusions: The assay demonstrated the selectivity, test range, precision, and linearity to perform reliable measurements of gemcitabine in plasma. The addition of stabilizer improved the sample handling. Using general clinical chemistry analyzers, gemcitabine could be measured for TDM." @default.
• W2605847125 created "2017-04-28" @default.
• W2605847125 creator A5008180481 @default.
• W2605847125 creator A5011561535 @default.
• W2605847125 creator A5019353224 @default.
• W2605847125 creator A5020883449 @default.
• W2605847125 creator A5022002713 @default.
• W2605847125 creator A5027371881 @default.
• W2605847125 creator A5035296183 @default.
• W2605847125 creator A5046795149 @default.
• W2605847125 creator A5051521014 @default.
• W2605847125 creator A5079557842 @default.
• W2605847125 creator A5085170224 @default.
• W2605847125 creator A5088208693 @default.
• W2605847125 date "2017-06-01" @default.
• W2605847125 modified "2023-10-03" @default.
• W2605847125 title "Rapid Homogeneous Immunoassay to Quantify Gemcitabine in Plasma for Therapeutic Drug Monitoring" @default.
• W2605847125 cites W1512724730 @default.
• W2605847125 cites W1809352789 @default.
• W2605847125 cites W1848316250 @default.
• W2605847125 cites W1890647543 @default.
• W2605847125 cites W1898871412 @default.
• W2605847125 cites W1905217126 @default.
• W2605847125 cites W1924785021 @default.
• W2605847125 cites W1931508686 @default.
• W2605847125 cites W1971473564 @default.
• W2605847125 cites W1992049899 @default.
• W2605847125 cites W2004869577 @default.
• W2605847125 cites W2021117435 @default.
• W2605847125 cites W2045149855 @default.
• W2605847125 cites W2050664701 @default.
• W2605847125 cites W2066444442 @default.
• W2605847125 cites W2068269280 @default.
• W2605847125 cites W2072930222 @default.
• W2605847125 cites W2074396493 @default.
• W2605847125 cites W2082821677 @default.
• W2605847125 cites W2089062211 @default.
• W2605847125 cites W2093004194 @default.
• W2605847125 cites W2093447536 @default.
• W2605847125 cites W2101965937 @default.
• W2605847125 cites W2102301778 @default.
• W2605847125 cites W2104998982 @default.
• W2605847125 cites W2109621731 @default.
• W2605847125 cites W2112163451 @default.
• W2605847125 cites W2129056290 @default.
• W2605847125 cites W2132865716 @default.
• W2605847125 cites W2133138738 @default.
• W2605847125 cites W2138804563 @default.
• W2605847125 cites W2140657981 @default.
• W2605847125 cites W2143771807 @default.
• W2605847125 cites W2143953275 @default.
• W2605847125 cites W2151253787 @default.
• W2605847125 cites W2165437060 @default.
• W2605847125 cites W2169388316 @default.
• W2605847125 cites W2312132282 @default.
• W2605847125 cites W4245831080 @default.
• W2605847125 doi "https://doi.org/10.1097/ftd.0000000000000402" @default.
• W2605847125 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5460533" @default.
• W2605847125 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28490046" @default.
• W2605847125 hasPublicationYear "2017" @default.
• W2605847125 type Work @default.
• W2605847125 sameAs 2605847125 @default.
• W2605847125 citedByCount "4" @default.
• W2605847125 countsByYear W26058471252017 @default.
• W2605847125 countsByYear W26058471252021 @default.
• W2605847125 countsByYear W26058471252022 @default.
• W2605847125 countsByYear W26058471252023 @default.
• W2605847125 crossrefType "journal-article" @default.
• W2605847125 hasAuthorship W2605847125A5008180481 @default.
• W2605847125 hasAuthorship W2605847125A5011561535 @default.
• W2605847125 hasAuthorship W2605847125A5019353224 @default.
• W2605847125 hasAuthorship W2605847125A5020883449 @default.
• W2605847125 hasAuthorship W2605847125A5022002713 @default.
• W2605847125 hasAuthorship W2605847125A5027371881 @default.
• W2605847125 hasAuthorship W2605847125A5035296183 @default.
• W2605847125 hasAuthorship W2605847125A5046795149 @default.
• W2605847125 hasAuthorship W2605847125A5051521014 @default.
• W2605847125 hasAuthorship W2605847125A5079557842 @default.
• W2605847125 hasAuthorship W2605847125A5085170224 @default.
• W2605847125 hasAuthorship W2605847125A5088208693 @default.
• W2605847125 hasBestOaLocation W26058471252 @default.
• W2605847125 hasConcept C112705442 @default.
• W2605847125 hasConcept C121608353 @default.
• W2605847125 hasConcept C126322002 @default.
• W2605847125 hasConcept C154020017 @default.
• W2605847125 hasConcept C159654299 @default.
• W2605847125 hasConcept C1621761 @default.
• W2605847125 hasConcept C185592680 @default.
• W2605847125 hasConcept C203014093 @default.
• W2605847125 hasConcept C2777844706 @default.
• W2605847125 hasConcept C2780258809 @default.
• W2605847125 hasConcept C2780272996 @default.
• W2605847125 hasConcept C2780420688 @default.
• W2605847125 hasConcept C43617362 @default.
• W2605847125 hasConcept C71924100 @default.
• W2605847125 hasConcept C89838059 @default.
• W2605847125 hasConcept C98274493 @default.
• W2605847125 hasConceptScore W2605847125C112705442 @default.

• next